Biological feasibility of measles eradication

Virus Research

Volumn 162, Issue 1-2, 2011, Pages 72-79

  Bellini, William J ^a   Rota, Paul A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Eradication; Measles; Molecular surveillance; Vaccine; Virus immunity

Indexed keywords

GLYCINE DEHYDROGENASE (DECARBOXYLATING); GUANINE NUCLEOTIDE BINDING PROTEIN; HEMAGGLUTININ; HYBRID PROTEIN; MATRIX PROTEIN; MEASLES VACCINE; NUCLEOPROTEIN; PHOSPHOPROTEIN; RNA POLYMERASE; VIRUS PROTEIN V;

DRUG EFFICACY; FEASIBILITY STUDY; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; LABORATORY; MEASLES; MOLECULAR EPIDEMIOLOGY; MOLECULAR STABILITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RUBELLA; VIROLOGY; VIRUS IMMUNITY; WORLD HEALTH ORGANIZATION;

ANTIBODIES, VIRAL; ANTIGENIC VARIATION; COMMUNICABLE DISEASE CONTROL; CROSS PROTECTION; DISEASE ERADICATION; HUMANS; MEASLES; MEASLES VACCINE; MEASLES VIRUS; MODELS, MOLECULAR; MOLECULAR EPIDEMIOLOGY; POPULATION SURVEILLANCE; VACCINATION; VIRAL PROTEINS; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

POLIOVIRUS; RINDERPEST VIRUS; VARIOLA VIRUS;

EID: 81555205777     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.09.023     Document Type: Review

References (100)

1. Anonymous Measles: United States, January-May 20, 2011. Morb. Mortal. Wkly Rep. 2011, 60(20):666-668.
2. Anonymous Notes from the field: measles outbreak - Hennepin County, Minnesota, February-March 2011. Morb. Mortal. Wkly Rep. 2011, 60(13):421.
3. Anonymous Notes from the field: measles outbreak - indiana, June-July 2011. Morb. Mortal. Wkly Rep. 2011, 60:1169.
4. Atrasheuskaya A.V., Kulak M.V., Neverov A.A., Rubin S., Ignatyev G.M. Measles cases in highly vaccinated population of Novosibirsk Russia, 2000-2005. Vaccine 2008, 26(17):2111-2118.
5. Audet S., Virata Theimer M., Beeler J., Scott D., Frazier D., Mikolajczyk M., Eller N., Chen F.-M., Yu M.-Y. Measles-virus-neutralizing antibodies in intravenous immunoglobulins. J. Infect. Dis. 2006, 194(6):781-789.
6. Aurpibul L., Puthanakit T., Sirisanthana T., Sirisanthana V. Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. Clin. Infect. Dis. 2010, 50(10):1415-1418.
7. Aversa G., Chang C.C., Carballido J.M., Cocks B.G., de Vries J.E. Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production. J. Immunol. 1997, 158(9):4036-4044.
8. Bankamp B., Bellini W.J., Rota P.A. Comparison of L proteins of vaccine and wild-type measles viruses. J. Gen. Virol. 1999, 80(7):1617-1625.
9. Bankamp B., Lopareva E.N., Kremer J.R., Tian Y., Clemens M.S., Patel R., Fowlkes A.L., Kessler J.R., Muller C.P., Bellini W.J., Rota P.A. Genetic variability and mRNA editing frequencies of the phosphoprotein genes of wild-type measles viruses. Virus Res. 2008, 135(2):298-306.
10. Bellini W.J., Englund G., Rozenblatt S., Arnheiter H., Richardson C.D. Measles virus P gene codes for two proteins. J. Virol. 1985, 53(3):908-919.
11. Bellini W.J., Helfand R.F. The challenges and strategies for laboratory diagnosis of measles in an international setting. J. Infect. Dis. 2003, 187(SUPPL. 1):S283-S290.
12. Bishai D., Johns B., Nair D., Nabyonga-Orem J., Fiona-Makmot B., Simons E., Dabbagh A. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda. J. Infect. Dis. 2011, 204(SUPPL. 1):S107-S115.
13. Brown K.E., Mulders M.N., Freymuth F., Santibanez S., Mosquera M.M., Cordey S., Beirnes J., Shulga S., Myers R., Featherstone D. Appearance of a novel measles G3 strain in multiple European countries within a two month period, 2010. Euro Surveill. 2011, 16(17).
14. Cathomen T., Mrkic B., Spehner D., Drillien R., Naef R., Pavlovic J., Aguzzi A., Billeter M.A., Cattaneo R. A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. EMBO J. 1998, 17(14):3899-3908.
15. Cathomen T., Naim H.Y., Cattaneo R. Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J. Virol. 1998, 72(2):1224-1234.
16. Cattaneo R., Kaelin K., Baczko K., Billeter M.A. Measles virus editing provides an additional cysteine-rich protein. Cell 1989, 56(5):759-764.
17. Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Preblud S.R., Orenstein W.A. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 1990, 162(5):1036-1042.
18. Cocks B.G., Chang C.C., Carballido J.M., Yssel H., de Vries J.E., Aversa G. A novel receptor involved in T-cell activation. Nature 1995, 376(6537):260-263.
19. de Quadros C., Andrus J., Danovaro Holliday M.C., Castillo-Solrzano C. Feasibility of global measles eradication after interruption of transmission in the Americas. Expert Rev. Vacc. 2008, 7(3):355-362.
20. Dorig R.E., Marcil A., Chopra A., Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993, 75(2):295-305.
21. Dowdle W.R. The principles of disease elimination and eradication. Bull World Health Organ. 1998, 76(SUPPL. 2):22-25.
22. Edmonson M.B., Addiss D.G., McPherson J.T., Berg J.L., Circo S.R., Davis J.P. Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA 1990, 263(18):2467-2471.
23. El Mubarak H.S., De Swart R.L., Osterhaus A.D., Schutten M. Development of a semi-quantitative real-time RT-PCR for the detection of measles virus. J. Clin. Virol. 2005, 32(4):313-317.
24. Enders J.F., Peebles T.C. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc. Soc. Exp. Biol. Med. 1954, 86(2):277-286.
25. Enquselassie F., Ayele W., Dejene A., Messele T., Abebe A., Cutts F.T., Nokes D.J. Seroepidemiology of measles in Addis Ababa, Ethiopia: implications for control through vaccination. Epidemiol. Infect. 2003, 130(3):507-519.
26. Featherstone D. Manual for the Diagnosis of Measles and Rubella Infection 2007, WHO. second ed.
27. Featherstone D.A., Rota P.A., Icenogle J., Mulders M.N., Jee Y., Ahmed H., de Filippis A.M., Ramamurty N., Gavrilin E., Byabamazima C., Dosseh A., Xu W., Komase K., Tashiro M., Brown D., Bellini W.J., Strebel P. Expansion of the global measles and rubella laboratory network 2005-09. J. Infect. Dis. 2011, 204(SUPPL. 1):S491-S498.
28. Ferreira C.S., Frenzke M., Leonard V.H., Welstead G.G., Richardson C.D., Cattaneo R. Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM CD150). J. Virol. 2010, 84(6):3033-3042.
29. Gay N. The theory of measles elimination: implications for the design of elimination strategies. J. Infect. Dis. 2004, 189(SUPPL. 1):S27-S35.
30. Giraudon P., Jacquier M.F., Wild T.F. Antigenic analysis of African measles virus field isolates: identification and localisation of one conserved and two variable epitope sites on the NP protein. Virus Res. 1988, 10(2-3):137-152.
31. Griffin D.A. Measles virus. Fields Virology 2007, vol. 2:1551-1585. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. 5th ed.
32. Harty R.N., Palese P. Measles virus phosphoprotein (P) requires the NH2- and COOH-terminal domains for interactions with the nucleoprotein (N) but only the COOH terminus for interactions with itself. J. Gen. Virol. 1995, 76(11):2863-2867.
33. Hashiguchi T., Ose T., Kubota M., Maita N., Kamishikiryo J., Maenaka K., Yanagi Y. Structure of the measles virus hemagglutinin bound to its cellular receptor SLAM. Nat. Struct. Mol. Biol. 2011, 18(2):135-141.
34. Helfand R.F., Gary H.E., Atkinson W.L., Nordin J.D., Keyserling H.L., Bellini W.J. Decline of measles-specific immunoglobulin M antibodies after primary measles, mumps, and rubella vaccination. Clin. Diagn. Lab. Immunol. 1998, 5(2):135-138.
35. Helfand R.F., Heath J.L., Anderson L.J., Maes E.F., Guris D., Bellini W.J. Diagnosis of measles with an IgM capture EIA: the optimal timing of specimen collection after rash onset. J. Infect. Dis. 1997, 175(1):195-199.
36. Helfand R.F., Kebede S., Gary H.E., Beyene H., Bellini W.J. Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Clin. Diagn. Lab. Immunol. 1999, 6(2):178-180.
37. Hickman C.J., Hyde T.B., Sowers S.B., Mercader S., McGrew M., Williams N.J., Beeler J.A., Audet S., Kiehl B., Nandy R., Tamin A., Bellini W.J. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals. J. Infect. Dis. 2011, 204(SUPPL. 1):S549-S558.
38. Hilleman M.R. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2001, 20(5-6):651-665.
39. Hilleman M.R., Buynak E.B., Weibel R.E., Stokes J., Whitman J.E., Leagus M.B. Development and evaluation of the Moraten measles virus vaccine. JAMA 1968, 206(3):587-590.
40. Hummel K.B., Lowe L., Bellini W.J., Rota P.A. Development of quantitative gene-specific real-time RT-PCR assays for the detection of measles virus in clinical specimens. J. Virol. Methods 2006, 132(1-2):166-173.
41. Hyde T.B., Nandy R., Hickman C.J., Langidrik J.R., Strebel P.M., Papania M.J., Seward J.F., Bellini W.J. Laboratory confirmation of measles in elimination settings: experience from the Republic of the Marshall Islands, 2003. Bull. World Health Organ. 2009, 87(2):93-98.
42. Kessler J.R., Kremer J.R., Shulga S.V., Tikhonova N.T., Santibanez S., Mankertz A., Semeiko G.V., Samoilovich E.O., Tamfum J.J., Pukuta E., Muller C.P. Revealing new measles virus transmission routes by use of sequence analysis of phosphoprotein and hemagglutinin genes. J. Clin. Microbiol. 2011, 49(2):677-683.
43. Kremer J.R., Brown K.E., Jin L., Santibanez S., Shulga S.V., Aboudy Y., Demchyshyna I.V., Djemileva S., Echevarria J.E., Featherstone D.F., Hukic M., Johansen K., Litwinska B., Lopareva E., Lupulescu E., Mentis A., Mihneva Z., Mosquera M.M., Muscat M., Naumova M.A., Nedeljkovic J., Nekrasova L.S., Magurano F., Fortuna C., de Andrade H.R., Richard J.L., Robo A., Rota P.A., Samoilovich E.O., Sarv I., Semeiko G.V., Shugayev N., Utegenova E.S., van Binnendijk R., Vinner L., Waku-Kouomou D., Wild T.F., Brown D.W., Mankertz A., Muller C.P., Mulders M.N. High genetic diversity of measles virus World Health Organization European Region, 2005-2006. Emerg. Infect. Dis. 2008, 14(1):107-114.
44. LeBaron C., Beeler J., Sullivan B., Forghani B., Bi D., Beck C., Audet S., Gargiullo P. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch. Pediatr. Adolesc. Med. 2007, 161(3):294-301.
45. Lemon K., de Vries R.D., Mesman A.W., McQuaid S., van Amerongen G., Yuksel S., Ludlow M., Rennick L.J., Kuiken T., Rima B.K., Geijtenbeek T.B., Osterhaus A.D., Duprex W.P., de Swart R.L. Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog. 2011, 7(1):e1001263.
46. Leonard V.H., Hodge G., Reyes-Del Valle J., McChesney M.B., Cattaneo R. Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J. Virol. 2010, 84(7):3413-3420.
47. Leonard V.H., Sinn P.L., Hodge G., Miest T., Devaux P., Oezguen N., Braun W., McCray P.B., McChesney M.B., Cattaneo R. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J. Clin. Invest. 2008, 118(7):2448-2458.
48. Levin A., Burgess C., Garrison L.P., Bauch C., Babigumira J., Simons E., Dabbagh A. Global eradication of measles: an epidemiologic and economic evaluation. J. Infect. Dis. 2011, 204(SUPPL. 1):S98-S106.
49. Liston P., DiFlumeri C., Briedis D.J. Protein interactions entered into by the measles virus P V, and C proteins. Virus Res. 1995, 38(2-3):241-259.
50. Mankertz A., Mihneva Z., Gold H., Baumgarte S., Baillot A., Helble R., Roggendorf H., Bosevska G., Nedeljkovic J., Makowka A., Hutse V., Holzmann H., Aberle S.W., Cordey S., Necula G., Mentis A., Korukluoglu G., Carr M., Brown K.E., Hubschen J.M., Muller C.P., Mulders M.N., Santibanez S. Spread of measles virus d4-hamburg, Europe, 2008-2011. Emerg. Infect. Dis. 2011, 17(8):1396-1401.
51. Moss W.J., Griffin D.E. Global measles elimination. Nat. Rev. Microbiol. 2006, 4(12):900-908.
52. Mühlebach, M.D., Mateo, M., Sinn, P., Prüfer, S., Uhlig, K., Leonard, V., Navaratnarajah, C., Frenzke, M., Wong, X., Sawatsky, B., Ramachandran, S., McCray, P., Cichutek, V., von Messling, V., Lopez, Cattaneo, R. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature, in press.
53. Mulders M.N., Nebie Y.K., Fack F., Kapitanyuk T., Sanou O., Valea D.C., Muyembe-Tamfum J.J., Ammerlaan W., Muller C.P. Limited diversity of measles field isolates after a national immunization day in Burkina Faso: progress from endemic to epidemic transmission?. J. Infect. Dis. 2003, 187(SUPPL. 1):S277-S282.
54. Mulders M.N., Truong A.T., Muller C.P. Monitoring of measles elimination using molecular epidemiology. Vaccine 2001, 19(17-19):2245-2249.
55. Naniche D., Varior-Krishnan G., Cervoni F., Wild T.F., Rossi B., Rabourdin-Combe C., Gerlier D. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 1993, 67(10):6025-6032.
56. Noyce R.S., Bondre D.G., Ha M.N., Lin L.-T., Sisson G., Tsao M.-S., Richardson C.D. Tumor cell marker PVRL4 (Nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 2011, 7(8):e1002240.
57. Ohuma E.O., Okiro E.A., Bett A., Abwao J., Were S., Samuel D., Vyse A., Gay N., Brown D.W.G., Nokes D.J. Evaluation of a measles vaccine campaign by oral-fluid surveys in a rural Kenyan district: interpretation of antibody prevalence data using mixture models. Epidemiol. Infect. 2009, 137(2):227-233.
58. Ozanne G., d'Halewyn M.A. Secondary immune response in a vaccinated population during a large measles epidemic. J. Clin. Microbiol. 1992, 30(7):1778-1782.
59. Ozoemena L.C., Minor P.D., Afzal M.A. Comparative evaluation of measles virus specific TaqMan PCR and conventional PCR using synthetic and natural RNA templates. J. Med. Virol. 2004, 73(1):79-84.
60. Pannuti C., Morello R., de Moraes J., Curti S., Afonso A.M.S., Camargo M.C.C., Souza V.A.U.F.d. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clin. Diagn. Lab. Immunol. 2004, 11(1):119-122.
61. Paunio M., Peltola H., Valle M., Davidkin I., Virtanen M., Heinonen O.P. Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees. Am. J. Epidemiol. 1998, 148(11):1103-1110.
62. Ratnam S., Tipples G., Head C., Fauvel M., Fearon M., Ward B.J. Performance of indirect immunoglobulin M (IgM) serology tests and IgM capture assays for laboratory diagnosis of measles. J. Clin. Microbiol. 2000, 38(1):99-104.
63. Richardson C., Hull D., Greer P., Hasel K., Berkovich A., Englund G., Bellini W., Rima B., Lazzarini R. The nucleotide sequence of the mRNA encoding the fusion protein of measles virus (Edmonston strain): a comparison of fusion proteins from several different paramyxoviruses. Virology 1986, 155(2):508-523.
64. Riddell M., Moss W., Hauer D., Monze M., Griffin D. Slow clearance of measles virus RNA after acute infection. J. Clin. Virol. 2007, 39(4):312-317.
65. Riddell M.A., Rota J.S., Rota P.A. Review of the temporal and geographical distribution of measles virus genotypes in the prevaccine and postvaccine eras. Virol. J. 2005, 2:87.
66. Rima B.K., Earle J.A., Yeo R.P., Herlihy L., Baczko K., ter Meulen V., Carabana J., Caballero M., Celma M.L., Fernandez-Munoz R. Temporal and geographical distribution of measles virus genotypes. J. Gen. Virol. 1995, 76(5):1173-1180.
67. Rota J.S., Heath J.L., Rota P.A., King G.E., Celma M.L., Carabana J., Fernandez-Munoz R., Brown D., Jin L., Bellini W.J. Molecular epidemiology of measles virus: identification of pathways of transmission and implications for measles elimination. J. Infect. Dis. 1996, 173(1):32-37.
68. Rota J.S., Hickman C.J., Sowers S.B., Rota P.A., Mercader S., Bellini W.J. Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission. J. Infect. Dis. 2011, 204(SUPPL. 1):S559-S563.
69. Rota J.S., Wang Z.D., Rota P.A., Bellini W.J. Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res. 1994, 31(3):317-330.
70. Rota P.A., Bellini W.J. Update on the global distribution of genotypes of wild type measles viruses. J. Infect. Dis. 2003, 187(SUPPL. 1):S270-S276.
71. Rota P.A., Brown K., Mankertz A., Santibanez S., Shulga S., Muller C.P., Hubschen J.M., Siqueira M., Beirnes J., Ahmed H., Triki H., Al-Busaidy S., Dosseh A., Byabamazima C., Smit S., Akoua-Koffi C., Bwogi J., Bukenya H., Wairagkar N., Ramamurty N., Incomserb P., Pattamadilok S., Jee Y., Lim W., Xu W., Komase K., Takeda M., Tran T., Castillo-Solorzano C., Chenoweth P., Brown D., Mulders M.N., Bellini W.J., Featherstone D. Global distribution of measles genotypes and measles molecular epidemiology. J. Infect. Dis. 2011, 204(SUPPL. 1):S514-S523.
72. Rota P.A., Brown K.E., Hubschen J.M., Muller C.P., Icenogle J., Chen M.H., Bankamp B., Kessler J.R., Brown D.W., Bellini W.J., Featherstone D. Improving global virologic surveillance for measles and rubella. J. Infect. Dis. 2011, 204(SUPPL. 1):S506-S513.
73. Rota P.A., Featherstone D.A., Bellini W.J. Molecular epidemiology of measles virus. Curr. Top. Microbiol. Immunol. 2009, 330:129-150.
74. Rota P.A., Liffick S.L., Rota J.S., Katz R.S., Redd S., Papania M., Bellini W.J. Molecular epidemiology of measles viruses in the United States, 1997-2001. Emerg. Infect. Dis. 2002, 8(9):902-908.
75. Sanders R., Dabbagh A., Featherstone D. Risk analysis for measles reintroduction after global certification of eradication. J. Infect. Dis. 2011, 204(SUPPL. 1):S71-S77.
76. Santibanez S., Niewiesk S., Heider A., Schneider-Schaulies J., Berbers G.A.M., Zimmermann A., Halenius A., Wolbert A., Deitemeier I., Tischer A., Hengel H. Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies?. J. Gen. Virol. 2005, 86(2):365-374.
77. Santibanez S., Tischer A., Heider A., Siedler A., Hengel H. Rapid replacement of endemic measles virus genotypes. J. Gen. Virol. 2002, 83(11):2699-2708.
78. Schneider-Schaulies J., Meulen V., Schneider-Schaulies S. Measles infection of the central nervous system. J. Neurovirol. 2003, 9(2):247-252.
79. Sedlmeier R., Neubert W.J. The replicative complex of paramyxoviruses: structure and function. Adv. Virus Res. 1998, 50:101-139.
80. Sheppeard V., Forssman B., Ferson M., Moreira C., Campbell Lloyd S., Dwyer D., McAnulty J. Vaccine failures and vaccine effectiveness in children during measles outbreaks in New South Wales, March-May 2006. Commun. Dis. Intell. 2009, 33(1):21-26.
81. Shirogane Y., Takeda M., Tahara M., Ikegame S., Nakamura T., Yanagi Y. Epithelial-mesenchymal transition abolishes the susceptibility of polarized epithelial cell lines to measles virus. J. Biol. Chem. 2010, 285(27):20882-20890.
82. Sidorenko S.P., Clark E.A. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. J. Immunol. 1993, 151(9):4614-4624.
83. Spielhofer P., Bachi T., Fehr T., Christiansen G., Cattaneo R., Kaelin K., Billeter M.A., Naim H.Y. Chimeric measles viruses with a foreign envelope. J. Virol. 1998, 72(3):2150-2159.
84. Stambos V., Leydon J., Riddell M., Clothier H., Catton M., Featherstone D., Kelly H. Evaluation of the World Health Organization global measles and rubella quality assurance program, 2001-2008. J. Infect. Dis. 2011, 204(SUPPL. 1):S499-S505.
85. Strebel P.M., Cochi S.L., Hoekstra E., Rota P.A., Featherstone D., Bellini W.J., Katz S.L. A world without measles. J. Infect. Dis. 2011, 204(SUPPL. 1):S1-S3.
86. Tahara M., Takeda M., Shirogane Y., Hashiguchi T., Ohno S., Yanagi Y. Measles virus infects both polarized epithelial and immune cells by using distinctive receptor-binding sites on its hemagglutinin. J. Virol. 2008, 82(9):4630-4637.
87. Tamin A., Rota P.A., Wang Z.D., Heath J.L., Anderson L.J., Bellini W.J. Antigenic analysis of current wild type and vaccine strains of measles virus. J. Infect. Dis. 1994, 170(4):795-801.
88. Tatsuo H., Ono N., Tanaka K., Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000, 406(6798):893-897.
89. Thomas B., Beard S., Jin L., Brown K.E., Brown D.W. Development and evaluation of a real-time PCR assay for rapid identification and semi-quantitation of measles virus. J. Med. Virol. 2007, 79(10):1587-1592.
90. Tipples G.A., Hamkar R., Mohktari-Azad T., Gray M., Parkyn G., Head C., Ratnam S. Assessment of immunoglobulin M enzyme immunoassays for diagnosis of measles. J. Clin. Microbiol. 2003, 41(10):4790-4792.
91. Uzicanin A., Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J. Infect. Dis. 2011, 204(SUPPL. 1):S133-S148.
92. WHO Standardization of the nomenclature for describing the genetic characteristics of wild-type measles viruses. Wkly Epidemiol. Rec. 1998, (73):265-272.
93. WHO Nomenclature for describing the genetic characteristics of wild-type measles viruses (update). Part I. Wkly Epidemiol. Rec. 2001, 76(32):242-247.
94. WHO Standardization of the nomenclature for genetic characteristics of wild-type rubella viruses. Wkly Epidemiol. Rec. 2005, 80(14):126-132.
95. WHO Update of standard nomenclature for wild-type rubella viruses, 2007. Wkly Epidemiol. Rec. 2007, 82(24):216-222.
96. WHO Global reductions in measles mortality 2000-2008 and the risk of measles resurgence. Wkly Epidemiol. Rec. 2009, 84(49):509-516.
97. WHO Monitoring progress towards measles elimination. Wkly Epidemiol. Rec. 2010, 85(49):490-494.
98. Wild T.F., Buckland R. Functional aspects of envelope-associated measles virus proteins. Curr. Top. Microbiol. Immunol. 1995, 191:51-64.
99. Xu W., Tamin A., Rota J.S., Zhang L., Bellini W.J., Rota P.A. New genetic group of measles virus isolated in the People's Republic of China. Virus Res. 1998, 54(2):147-156.
100. Yanagi Y., Takeda M., Ohno S., Hashiguchi T. Measles virus receptors. Curr. Top. Microbiol. Immunol. 2009, 329:13-30.